Pharmafile Logo
Pharmafocus logo
Advanced Search

Biogen

Showing 15 posts of 117 posts found.

anirvan_ghosh

Biogen swoops to appoint Ex-Roche Vice President

March 16, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen

Biogen have appointed Anirvan Ghosh to the position of Senior Vice President of research and Early Development. Ghosh is slated …

Appointment

NICE reverses decision on medication for relapsing multiple sclerosis

March 16, 2017
Sales and Marketing Biogen, zinbryta

The current topic of discussion regarding NICE is how its recent changes will impact patient access to medicine but, away …

News
abbvie_0

UK High Court rules against AbbVie’s Humira patents

March 6, 2017
Sales and Marketing AbbVie, Biogen, Fujifilm Kyowa Kirin Biologics, Humira, Samsung Bioepis, biosimilar

The UK High Court has ruled that two of AbbVie patents, related to dosing regimens for rheumatoid arthritis, psoriasis and …

News
biogen_austria_238

Biogen shells out $1.25bn to protect best-selling MS drug

January 18, 2017
Research and Development, Sales and Marketing Biogen, Forward Pharma, multiple sclerosis, tecfidera

Biogen has announced it is to pay $1.25 billion to Copenhagen-based biotech Forward Pharma in the latest development in a …

News

Biogen’s gains late-year drug approval first for controversially expensive drug

January 3, 2017
Manufacturing and Production, Sales and Marketing Biogen, FDA

The FDA squeezed in one last approval before the year ended with the first approval for a drug to treat …

News
shutterstock_311949818

Neurodegenerative market to be worth $45 billion by 2022

December 12, 2016
Sales and Marketing Biogen, GBI Research, Novartis, Roche, Sanofi, neurodegenerative

Neurodegenerative disorders including Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) form a lucrative worldwide market which …

News
biogen_austria_238

Biogen and Ionis’ spinal muscular atrophy drug meets primary endpoint

November 7, 2016
Manufacturing and Production, Research and Development Biogen, Ionis, spinal muscular atrophy

Biogen and Ionis Pharmaceuticals have released news that their investigational treatment for spinal muscular atrophy (SMA), Spinraza (nusinersen), met the …

News
biogen_austria_238

Biogen closes in on bringing muscular atrophy preventing drug to market

September 26, 2016
Manufacturing and Production, Research and Development Biogen, EMA, FDA, Nusinersen

Biogen has applied for Priority Review, which, if granted, would shorten the review period necessary for nusinersen. They also plan …

News

FDA fast track designation for Biogen’s investigational Alzheimer’s treatment

September 2, 2016
Medical Communications, Research and Development Alzheimer's, Alzheimer’s, Biogen, FDA, aducanumab, fast track

Biogen has announced that its investigational Alzheimer’s disease treatment aducanumab has been granted fast track designation by the FDA. The …

News
biogen_austria_238

Biogen names haemophilia spin-off Bioverativ

August 10, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Biogen, bioverativ

Biogen has announced that Bioverativ will be the name of the standalone spin-off of its haemophilia and other blood disorders …

News
biogen_austria_238

Takeover rumours send Biogen’s stock soaring

August 3, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Biogen, MSD, rumours, takeover

Rumours have begun to circulate that companies including MSD and Allergan are plotting a takeover bid for Biogen, after a …

News
biogen_austria_238

Success for Biogen, Ionis as spinal muscular atrophy drug performs in Phase III

August 2, 2016
Manufacturing and Production, Research and Development Biogen, Ionis, phase III, spinal muscular atrophy

Biogen and Ionis Pharmaceuticals have announced that their spinal muscular atrophy treatment, nusinersen, met its primary endpoint at an interim …

News
biogen_austria_238

George Scangos to step down as Biogen CEO

July 21, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Biogen, George Scangos

In a surprising move, Biogen used the publishing of some promising second quarter results to announce the departure of CEO …

News
logo_400x400

Biogen and AbbVie’s Zinbryta gets European backing to treat multiple sclerosis

July 7, 2016
Research and Development, Sales and Marketing Biogen, drug approval, european union, multiple sclerosis, zinbryta

Biogen (Nasdaq: BIIB) and Abbvie’s (NYSE: ABBV) once-monthly Zinbryta (daclizumab) has been approved in European Union for treatment of multiple …

News
stocks1

Weekly Movers: Lion Biotech, Adamis, Sarepta…

June 13, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Alexion, Biogen, Shares, Stock Markets, Stock Movement, drug trial, sarepta

Drug trial results remained the important theme over the past week with several companies announcing key study results. The trial …

Feature
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026